Olema stock soared Tuesday after Roche reported strong clinical results for its breast cancer drug. An Oppenheimer analyst sees significant further upside in OLMA shares to $45.

The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.

Olema Pharmaceuticals (OLMA) surges after Roche's breast cancer data, but caution is urged as key clinical results are ...

Roche AG’s Genentech unit landed another clinical victory with giredestrant that provided a major stock boost for competitor Olema Pharmaceuticals Inc. Made public were positive phase III data from ...

According to DataM Intelligence AUSTIN, Texas and TOKYO, Nov. 18, 2025 /PRNewswire/ -- DataM Intelligence announces the latest insights into the rapidly transforming Oncology Molecular Diagnostics ...

FDA approves Poherdy, the first interchangeable biosimilar for Perjeta, enhancing competition in HER2-positive breast cancer ...

Roche RHHBY announced positive data from the late-stage lidERA Breast Cancer study on pipeline candidate giredestrant.

Roche claimed the results make its drug giredestrant the first of its kind, a so-called oral SERD, to show a benefit in the ...

European shares fell on Tuesday, with those in Germany near a five-month low as a broad risk-off mood gripped global markets, ...

Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a ...

Olema Pharmaceuticals stock surged 197% after Roche reported positive trial results for a similar breast cancer drug.